NBTX
Nanobiotix S.A.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Nanobiotix S.A.
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
No peers for Nanobiotix S.A. yet.
No peers for Nanobiotix S.A. yet.
Annual filing, covered
20-F parsed · Mar 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Mar 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
News
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.
Nanobiotix S.A.
30.02
| Manager | Value | % base | |
|---|---|---|---|
| Johnson & Johnson | $212.0M | 97.09% | 0.00% |
| Morgan Stanley | $1.9M | 0.86% | +37.26% |
| Jane Street | $1.2M | 0.56% | new |
| HRT Financial | $1.0M | 0.47% | new |
| XTX Topco | $597,734 | 0.27% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Johnson & Johnson | $212.0M | 97.09% | 0.00% |
| Morgan Stanley | $1.9M | 0.86% | +37.26% |
| Jane Street | $1.2M | 0.56% | new |
| HRT Financial | $1.0M | 0.47% | new |
| XTX Topco | $597,734 | 0.27% | new |
+0.21%
shares held · 10 largest managers